MedTrace Logo

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

NCT06686394 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2026-05-22

No results posted yet for this study

Summary

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:

* About the safety and how well people tolerate of patritumab deruxtecan
* How many people have the cancer respond (get smaller or go away) to treatment

Conditions

Interventions

BIOLOGICAL

Patritumab deruxtecan

Patritumab deruxtecan administered via IV infusion

BIOLOGICAL

Trastuzumab

Trastuzumab administered via IV infusion

BIOLOGICAL

Trastuzumab Biosimilar

Trastuzumab biosimilar administered via IV infusion

BIOLOGICAL

Pertuzumab

Pertuzumab administered via IV infusion

BIOLOGICAL

Tucatinib

Tucatinib administered as oral tablets

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-26
Primary Completion
2030-04-18
Completion
2030-04-18
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Israel
  • Japan
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06686394 on ClinicalTrials.gov